Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 9/20 | 0.51 |
| ▸ | CA2 | P00918 | 9/20 | 0.51 |
| ▸ | CA9 | Q16790 | 6/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | CA5A | P35218 | 2/20 | 0.50 |
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.41 |
| ▸ | SRC | P12931 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 2/20 | 0.40 |
| ▸ | CA6 | P23280 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9850273 | 0.86 | LMNA (0.44) | CA1CA2CA9LMNACA5A | |
| SCHEMBL277752 | 0.85 | LMNA (0.52) | CA1CA2LMNACES2CES1 | |
| SCHEMBL3631033 | 0.83 | BCAT2 (0.51) | CA1CA2LMNACES2CES1 | |
| SCHEMBL2593899 | 0.81 | LMNA (0.47) | CA1CA2LMNACES2CES1 | |
| SCHEMBL16339817 | 0.81 | LMNA (0.47) | CA1CA2LMNACES2CES1 | |
| SCHEMBL11896558 | 0.80 | CYP1A2 (0.54) | CA1CA2CA9LMNACES2 | |
| SCHEMBL13281027 | 0.78 | LMNA (0.45) | CA1CA2LMNACES2CES1 | |
| SCHEMBL28770861 | 0.78 | LMNA (0.45) | LMNACES2CES1MAPK1SRC | |
| SCHEMBL11033197 | 0.77 | CA1 (0.59) | CA1CA2CA9CA5ACA12 | |
| SCHEMBL28746292 | 0.77 | LMNA (0.44) | CA1CA2CA9LMNACES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240009153-A1 | BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | NEUROPRO THERAPEUTICS, INC. | 2024-01-11 | — | — | US | disclosed |
| EP-4072532-A1 | DOSAGE FORM FOR USE IN TREATING OR PREVENTING OF A DISEASE | Evonik Operations GmbH (DE) | 2022-10-19 | — | — | EP | disclosed |
| US-20200223854-A1 | BICYCLIC COMPOUNDS AS DUAL ATX/CA INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2020-07-16 | — | — | US | disclosed |
| US-10647719-B2 | Bicyclic compounds as dual ATX/CA inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2020-05-12 | — | — | US | disclosed |
| EP-2887806-B1 | METHOD OF TREATING AND PREVENTING BRAIN IMPAIRMENT USING NA+-K+ -2CI- COTRANSPORTER ISOFORM 1 INHIBITORS | UNIV ROCHESTER (US) | 2019-11-13 | — | — | EP | disclosed |
| US-20190151263-A1 | BUMETANIDE ANALGOS, COMPOSITIONS, AND METHODS OF USE | NEUROPRO THERAPEUTICS INC (US) | 2019-05-23 | — | — | US | disclosed |
| US-20180215765-A1 | NEW BICYCLIC COMPOUNDS AS DUAL ATX/CA INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2018-08-02 | — | — | US | disclosed |
| US-20170246131-A1 | BUMETANIDE ANALOGS, COMPOSITIONS, AND METHODS OF USE | NEUROPRO THERAPEUTICS INC (US) | 2017-08-31 | — | — | US | disclosed |
| US-9682928-B2 | Bumetanide analogs, compositions and methods of use | NEUROPRO THERAPEUTICS, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-9616075-B2 | Method of treating and preventing brain impairment using Na+-K+-2Cl-cotransporter isoform 1 inhibitors | UNIVERSITY OF ROCHESTER (US) | 2017-04-11 | — | — | US | disclosed |
| US-20150080350-A1 | BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | NEUROPRO THERAPEUTICS INC. | 2015-03-19 | — | — | US | disclosed |
| WO-2014014519-A1 | METHOD OF TREATING AND PREVENTING BRAIN IMPAIRMENT USING NA+-K+ -2CI- COTRANSPORTER ISOFORM 1 INHIBITORS | UNIVERSITY OF ROCHESTER (US) | 2014-01-23 | — | — | WO | disclosed |
| EP-2598478-A2 | ARYLSULFONAMIDE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE | Neurotherapeutics Pharma, Inc. (US) | 2013-06-05 | — | — | EP | disclosed |
| WO-2013059648-A1 | 2,3,5 TRISUBSTITUTED ARYL AND HETEROARYL AMINO DERIVATIVES, COMPOSITIONS, AND METHODS OF USE | NEUROTHERAPEUTICS PHARMA, INC. (US) | 2013-04-25 | — | — | WO | disclosed |
| WO-2012018635-A2 | ARYLSULFONAMIDE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE | NEUROTHERAPEUTICS PHARMA, INC. (US) | 2012-02-09 | — | — | WO | disclosed |
| US-20120004225-A1 | BUMETANIDE, FUROSEMIDE, PIRETANIDE, AZOSEMIDE, AND TORSEMIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | NEUROTHERAPEUTICS PHARMA, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| EP-2389371-A2 | BUMETANIDE, FUROSEMIDE, PIRETANIDE, AZOSEMIDE, AND TORSEMIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | Neurotherapeutics Pharma, Inc. (US) | 2011-11-30 | — | — | EP | disclosed |
| WO-2010085352-A2 | BUMETANIDE, FUROSEMIDE, PIRETANIDE, AZOSEMIDE, AND TORSEMIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | NEUROTHERAPEUTICS PHARMA, INC. (US) | 2010-07-29 | — | — | WO | disclosed |
| WO-2006011719-A1 | N-SUBSTITUTED-SULFAMOYLBENZOIC ACID DERIVATIVES, METHOD FOR PREPARING THEREOF AND ANTIVIRAL PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | B & C BIOPHARM CO., LTD. (KR) | 2006-02-02 | — | — | WO | disclosed |
| US-4161531-A | Diuretic and saluretic 5-sulfamoylbenzoic acid derivatives carrying a heterocyclic substituent | HOECHST AKTIENGESELLSCHAFT (DE) | 1979-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200223854-A1 | BICYCLIC COMPOUNDS AS DUAL ATX/CA INHIBITORS | ATXN2, ATXN2L, ATXN10 | CA1 1155/4885CA2 238/4885CA9 1224/4885 |
| US-20240009153-A1 | BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | SLC6A1, SLC6A13, SLC6A11 | CA1 988/4885CA2 489/4885CA9 743/4885 |
| US-20170246131-A1 | BUMETANIDE ANALOGS, COMPOSITIONS, AND METHODS OF USE | SLC6A1, SLC6A13, SLC6A11 | CA1 1022/4885CA2 471/4885CA9 710/4885 |
| US-20190151263-A1 | BUMETANIDE ANALGOS, COMPOSITIONS, AND METHODS OF USE | SLC6A1, SLC6A11, SLC6A13 | CA1 701/4885CA2 388/4885CA9 641/4885 |
| US-20120004225-A1 | BUMETANIDE, FUROSEMIDE, PIRETANIDE, AZOSEMIDE, AND TORSEMIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | ABCG2, ABCB1, TRPV1 | CA1 1755/4885CA2 1572/4885CA9 1396/4885 |
| US-20180215765-A1 | NEW BICYCLIC COMPOUNDS AS DUAL ATX/CA INHIBITORS | ATXN2, ATXN2L, ATXN10 | CA1 1536/4885CA2 473/4885CA9 1774/4885 |
| US-20150080350-A1 | BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | SLC6A1, SLC6A13, SLC6A11 | CA1 1762/4885CA2 1422/4885CA9 1040/4885 |
| US-10647719-B2 | Bicyclic compounds as dual ATX/CA inhibitors | ATXN2, ATXN2L, ATXN10 | CA1 1155/4885CA2 238/4885CA9 1224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.